Pressmeddelande

BioStock: Alligator Bioscience’s CSO presents CD40 portfolio at summit

Cision Publicerad: 14 Jul 2023 13:01

Alligator Bioscience’s CD40 agonist mitazalimab has recently shown promising results in a second interim analysis of the OPTIMIZE-1 phase II study in pancreatic cancer. The results will be presented by CSO Peter Ellmark at the 3rd Annual Tumour Myeloid-Directed Therapies Summit in Boston. His presentation also features the company’s bispecific CD40/CEACAM5 antibody ATOR-4066 and its potential to induce strong anti-tumour response in patients with CEACAM5-expressing tumours. BioStock contacted Peter Ellmark to get to know more.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/07/alligator-biosciences-cso-presents-cd40-portfolio-at-summit/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Nyheter om Alligator Bioscience

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!